Blogs

In part 1 of this two part paper, we indicated that even as the western markets are opening up to mAb biosimilars, Indian biosimilar companies have focused on home turfs. In the absence of a crystal ball and presence of several caveats, there is no telling how the market will shape Continue Reading
 Categories : Biosimilars, Disease Area Strategy Posted by Richa Agrawal  , ,
In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be Continue Reading
 Categories : ASCO17, ASCO18, Oncology Posted by Sakshi Saini  
Biosimilar The India Story
Conspicuous By Absence In US And EU The floodgates have opened for the first wave of the monoclonal antibody (mAb) biosimilars in the two most rewarding pharmaceutical markets US and EU. As several big pharmaceutical companies are gearing up for the opportunity, the Indian companies are conspicuous by their absence. Continue Reading
 Categories : Biosimilars, Disease Area Strategy Posted by Richa Agrawal  
An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market.  With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early Continue Reading
 Categories : ASCO17, Oncology Posted by Preeti Parikh  ,
Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric Continue Reading
 Categories : ASCO17, Oncology Posted by Nirmala Vittaladevuni  ,
Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound Continue Reading
 Categories : ASCO17, Oncology Posted by Nirmala Vittaladevuni  ,